Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03940963 · ClinicalTrials.gov registry record · NA
Study of AxoGuard® Nerve Cap and Neurectomy for Treatment of Symptomatic Neuroma & Prevention of Recurrent Neuroma Pain
A NA study, sponsored by Axogen Corporation.
- Completed
- Registry status
- NA
- Development phase
- 86
- Enrollment target
NCT03940963 is a NA study that has completed, run by Axogen Corporation. The registered enrollment target is 86 participants.
The verdict
NCT03940963, a NA study, has completed, sponsored by Axogen Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 86 participants
- Enrollment target
Study Summary
Comparing safety, pain, user experience, healthcare economic costs, work productivity, impairment and quality of life outcomes between Axoguard® Nerve Cap and neurectomy in the treatment of symptomatic neuromas in the foot or ankle. Study consists of 86 subjects randomized between the treatment groups followed for 12 months.
Interventions
- DEVICE AxoGuard® Nerve Cap
- PROCEDURE Standard Neurectomy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2018-10-10 |
| Est. Completion | 2023-07-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03940963
The ClinicalTrials.gov registry entry for NCT03940963 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Axogen Corporation, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AxoGuard® Nerve Cap is the first listed.
NCT03940963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03940963 about?
NCT03940963 is a clinical study titled "Study of AxoGuard® Nerve Cap and Neurectomy for Treatment of Symptomatic Neuroma & Prevention of Recurrent Neuroma Pain". Comparing safety, pain, user experience, healthcare economic costs, work productivity, impairment and quality of life outcomes between Axoguard® Nerve Cap and neurectomy in the treatment of symptomatic neuromas in the foot or ankle. Study consists of 86 subjects randomized between the treatment grou...
What is the current status of trial NCT03940963?
This trial is currently completed. It is a NA study. The enrollment target is 86 participants. The study started on 2018-10-10. Estimated completion is 2023-07-17.
What interventions are being tested in trial NCT03940963?
The interventions under investigation include: AxoGuard® Nerve Cap (DEVICE), Standard Neurectomy (PROCEDURE).
Who is sponsoring clinical trial NCT03940963?
This trial is sponsored by Axogen Corporation, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.